|
Search
Search through the thousands of lawsuits, complaints and recalls on our site.
 |
Case ID: 659 | Drugs / Medical | 08/15/2005
Kahn Gauthier Swick is investigating possible legal actions against Hoffman-La Roche, Inc., manufacturer of the prescription acne drug Accutane, to recover for psychological damage--sometimes leading to suicide--suffered by Accutane users. As of late 2000, the federal Food and Drug Administration (FDA) had received reports of 66 suicides and 1,373 other psychiatric adverse events in Accutane users. Accutane was approved in 1982 to treat only a very special type of acne--severe nodular acne that had not responded to other therapies. Critics estimate that most of the 500,000 people in the United States who try it each year have acne too mild for the drug.
The possible connection between Accutane and suicide became national news in October, 2000, after U.S. Rep. Bart Stupak from Michigan said that his 17-year-old son's suicide earlier that year might be linked to Accutane. Bart Stupak Jr., known as 'B.J.,' shot himself in the head with his father's gun in the early hours of May 14. Stupak, a football player who was popular in school, killed himself after a prom-night party. Other Accutane victims have spoken out: 'Within days of taking Accutane, my mood began to change. Within weeks, I was crying,' testified Amanda Callais of Denham Springs, Louisiana, who at age 14 attempted suicide, two months after beginning Accutane therapy. Before taking Accutane, she was an outgoing, happy, straight-A student. According to her mother, within days after throwing out the pills, Amanda made 'a miraculous recovery.' Stacy and Michael Baumann of Mundelein, Ill., whose son, Daniel, a high school sophomore, killed himself in December, 1999 while taking Accutane, have described how their dermatologist handed out outdated brochures and their pharmacist provided no counseling. Register your Hoffman La Roche Accutane ComplaintIf you or someone you know has been affected by this case, you may qualify for a money settlement as the result of your financial/economic or other damages that may be awarded either prior to a lawsuit or after the initiation of a lawsuit either currently in progress or filed just for you, possibly a class action lawsuit. Please simply register your complaint by clicking here for Hoffman La Roche Accutane, or click the red "submit" button on this page, and a lawyer will review your Hoffman La Roche Accutane complaint. By submitting your complaint, you are asking lawyers to contact you. You are under no obligation to accept their services and you are free to choose which lawyer you want to work with. Lawyers are usually paid out of the proceeds of the settlement or verdict rendered - the lawyers work on "contingency" by fronting the costs of your lawsuit based on their belief that they will recover a settlement for you. At Lawcash.com, it is our goal to keep you informed about important legal cases, class actions and settlements. Our lawyers offer free legal evaluations in tort cases, class actions, personal injury, and other lawsuits because we are dedicated to helping you resolve your legal complaints. Other Drugs / Medical Cases of Interest Several class actions have been filed against biopharmaceutical company IntraBiotics Pharmaceuticals, Inc., (Nasdaq:IBPI) and certain of its officers and directors by stockholders who purchased the company's common stock between September 5, 2003, and June 22, 2004. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities. Several class actions have been filed against drug manufacturer Ligand Pharmaceuticals, Inc. (Nasdaq:LGND), and certain of its officers and directors by stockholders who purchased the company's common stock between July 28, 2003, and August 2, 2004. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities. Several class actions have been filed against biotechnology company Cerus Corporation (Nasdaq: CERS) and certain of its officers and directors by stockholders who purchased the company's common stock between October 25, 2000, and September 3, 2003. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities. The stockholders seek to recover compensatory damages for the loss of value of their stock. A federal class action has been filed against the Kentucky based Trover Clinic Foundation and its associated network of hospitals and medical officers. The suit alleges that over 415 individuals who sued Trover Clinic in state court were subsequently contacted and told that they would not be treated at any Trover affiliated facility unless they accepted the terms of a settlement offer put forward by Trover. Many of the plaintiffs are cancer patients who would have been forced to seek treatment out of state as a result of Trover's refusal to treat them. Judgment has been entered against United HealthCare Services, Inc. and its insurer-sibling HealthCare Insurance Company on behalf of participants in pharmacy benefit plans governed by the federal Employee Retirement Income Security Act and administered by United. The action asks United to provide reimbursement for drug overcharges that occurred when the plan administrator failed to pass on its negotiated prices to participants. Monetary damages will not be distributed until all proceedings have been finalized and all possible appeals have been exhausted. Kahn Gauthier Swick, LLC ("Kahn Gauthier") today announced that it filed a class action lawsuit in the United States District Court for the Eastern District of Louisiana on behalf of purchasers of OCA, Inc. ("OCA" or "the Company") (NYSE:OCA) common stock during the period between May 18, 2004 and June 6, 2005 (the "Class Period").
|
IT'S FREE
|
© 2000 - 2008 Copyright. All rights reserved nola3, llc.
